Last reviewed · How we verify

NCT03455374: DIAMOND-PAD

Diamondback in Peripheral Vascular Disease

Terminated NA Last updated 27 June 2019
What this trial tests

NA trial testing Treatment with CSI atherectomy device in Peripheral Vascular Diseases in 10 participants. Terminated before completion.

Timeline
8 August 2017
Primary endpoint
13 May 2019
13 May 2019

Quick facts

Lead sponsorArkansas Heart Hospital
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment10
Start date8 August 2017
Primary completion13 May 2019
Estimated completion13 May 2019
Sites2 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Arkansas Heart Hospital

Who can join

18 and older, any sex, with Peripheral Vascular Diseases or Critical Limb Ischemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, nonrandomized, single-arm study using CSI Orbital Atherectomy System in patients with PAD (total occlusions or significant stenosis). Patients will be enrolled if they have claudication and/or critical limb ischemia, and identifiable PAD disease with moderate to severe calcification on Computer Tomography Angiogram (PCA) or peripheral angiogram requiring percutaneous peripheral intervention (PPI).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Peripheral Vascular Diseases

Currently open trials in the same condition.

Other Arkansas Heart Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03455374.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing